Portal de Periódicos da CAPES

Transcatheter Aortic Valve Implantation With the New Balloon-Expandable Sapien 3 Versus Sapien XT Valve System

2015; Lippincott Williams & Wilkins; Volume: 8; Issue: 6 Linguagem: Inglês

10.1161/circinterventions.115.002408

1941-7632

Freek Nijhoff, Masieh Abawi, Pierfrancesco Agostoni, Faiz Ramjankhan, Pieter A. Doevendans, Pieter R. Stella,

Cardiac Imaging and Diagnostics

Background— The new balloon-expandable Sapien 3 transcatheter heart valve (S3-THV) incorporates new features to reduce aortic regurgitation (AR) and vascular complications in transcatheter aortic valve implantation. Aim of this study is to compare the outcomes of the S3-THV with the preceding Sapien XT THV (SXT-THV) in patients who underwent transcatheter aortic valve implantation for symptomatic severe native aortic stenosis. Methods and Results— Eligible patients were retrospectively identified in our institutional database and periprocedural clinical and imaging data were collected. Non-parsimonious one-to-many propensity score matching was performed to account for differences in baseline characteristics. Between November 2011 and December 2014, 167 patients underwent balloon-expandable transcatheter aortic valve implantation with either the S3-THV (n=49) or SXT-THV (n=118). Forty-four (89.8%) S3-THV patients were matched to 66 (55.9%) SXT-THV patients (mean age 80.3±8.4 and 80.5±7.8 years, median EuroSCORE 15.8 and 16.5%, respectively). In the S3-THV and SXT-THV groups, transfemoral approach (77.3% versus 78.8%) and postdilatation rates (15.9% versus 12.1%) were similar. Predischarge echocardiography demonstrated a lower incidence of ≥mild AR (15.9% versus 46.2%, P =0.003) for the S3-THV, despite reduced annulus area to prosthesis oversizing (8.2±5.1 versus 18.2±10.7%, P =0.001). Transfemoral access site–related life-threatening or major bleedings and vascular complications were absent in the S3-THV group (0% versus 7.7%, P =0.15). No differences were observed in pacemaker implantation rate (9.8% versus 8.8%, P =0.94) and 30-day mortality (both 5%). Conclusions— In this retrospective, propensity score–matched analysis, the S3-THV performed superiorly to the SXT-THV, as demonstrated by improved valve patency and increased transfemoral access safety.